Arete Wealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,696
| Closed | -$455K | – | 495 |
|
|
2025
Q4 | $455K | Buy |
2,696
+825
| +44% | +$134K | 0.03% | 469 |
|
|
2025
Q3 | $270K | Sell |
1,871
-35
| -2% | -$4.78K | 0.02% | 633 |
|
|
2025
Q2 | $241K | Sell |
1,906
-146
| -7% | -$17.9K | 0.02% | 632 |
|
|
2025
Q1 | $262K | Buy |
2,052
+62
| +3% | +$8.41K | 0.02% | 584 |
|
|
2024
Q4 | $263K | Buy |
1,990
+80
| +4% | +$11.2K | 0.02% | 603 |
|
|
2024
Q3 | $277K | Sell |
1,910
-179
| -9% | -$25.9K | 0.02% | 545 |
|
|
2024
Q2 | $286K | Buy |
+2,089
| New | +$279K | 0.02% | 545 |
|
|
2024
Q1 | – | Sell |
-2,115
| Closed | -$287K | – | 519 |
|
|
2023
Q4 | $287K | Buy |
+2,115
| New | +$258K | 0.02% | 562 |
|
|
2023
Q3 | – | Sell |
-1,651
| Closed | -$210K | – | 597 |
|
|
2023
Q2 | $210K | Sell |
1,651
-422
| -20% | -$54.8K | 0.02% | 582 |
|
|
2023
Q1 | $268K | Buy |
2,073
+106
| +5% | +$13.9K | 0.02% | 503 |
|
|
2022
Q4 | $258M | Sell |
1,967
-63
| -3% | -$8.14K | 0.02% | 498 |
|
|
2022
Q3 | $237K | Sell |
2,030
-1,836
| -47% | -$228K | 0.02% | 477 |
|
|
2022
Q2 | $464K | Buy |
+3,866
| New | +$459K | 0.05% | 258 |
|
|
2020
Q4 | – | Sell |
-3,940
| Closed | -$527K | – | 422 |
|
|
2020
Q3 | $527K | Buy |
3,940
+388
| +11% | +$52.6K | 0.08% | 204 |
|
|
2020
Q2 | $486K | Buy |
+3,552
| New | +$453K | 0.08% | 222 |
|
|
2020
Q1 | – | Sell |
-2,899
| Closed | -$349K | – | 377 |
|
|
2019
Q4 | $349K | Buy |
+2,899
| New | +$323K | 0.06% | 278 |
|
|
2019
Q3 | – | Sell |
-1,987
| Closed | -$217K | – | 424 |
|
|
2019
Q2 | $217K | Buy |
1,987
+108
| +6% | +$11.5K | 0.04% | 353 |
|
|
2019
Q1 | $210K | Buy |
+1,879
| New | +$206K | 0.04% | 351 |
|
|
2018
Q4 | – | Sell |
-1,833
| Closed | -$224K | – | 386 |
|
|
2018
Q3 | $224K | Sell |
1,833
-380
| -17% | -$44.7K | 0.05% | 320 |
|
|
2018
Q2 | $243K | Buy |
+2,213
| New | +$237K | 0.06% | 312 |
|
|
2018
Q1 | – | Sell |
-48,263
| Closed | -$5.15M | – | 333 |
|
|
2017
Q4 | $5.15M | Buy |
+48,263
| New | +$5.16M | 1.68% | 10 |
|
|
2015
Q3 | – | Sell |
-3,150
| Closed | -$387K | – | 139 |
|
|
2015
Q2 | $387K | Sell |
3,150
-1,008
| -24% | -$121K | 0.26% | 82 |
|
|
2015
Q1 | $476K | Buy |
+4,158
| New | +$459K | 0.31% | 78 |
|
Other funds holding IBB
CB
Arete Wealth Advisors's IBB Position: Q1 2026 in Review
Arete Wealth Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 2,696 shares — an estimated $455K sold.
Arete Wealth Advisors first reported a position in IBB in Q1 2015 and held it in 23 quarters. The position peaked at $258M in Q4 2022. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Arete Wealth Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
- Arete Wealth Advisors sold 2,696 iShares Biotechnology ETF shares in Q1 2026, an estimated $455K.
- Arete Wealth Advisors first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 23 quarters.
- Arete Wealth Advisors's iShares Biotechnology ETF position peaked at $258M in Q4 2022.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.